Joseph G Jurcic

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. doi request reprint Radioimmunotherapy for hematopoietic cell transplantation
    Joseph G Jurcic
    Columbia University Medical Center, 177 Fort Washington Avenue, 6 435, New York, NY 10032, USA
    Immunotherapy 5:383-94. 2013
  2. pmc Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    Todd L Rosenblat
    Department of Medicine and the Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5303-11. 2010
  3. pmc Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses
    Nicole Lamanna
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:491-7. 2009
  4. doi request reprint Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
    Azra Raza
    St Vincent s Comprehensive Cancer Center, New York, NY, USA
    Leuk Lymphoma 50:1336-44. 2009
  5. ncbi request reprint Immunotherapy for acute myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 458, New York, NY 10021, USA
    Curr Oncol Rep 7:339-46. 2005
  6. ncbi request reprint The promise of targeted {alpha}-particle therapy
    Deborah A Mulford
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:199S-204S. 2005
  7. ncbi request reprint Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Nicole Lamanna
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:1575-81. 2006
  8. ncbi request reprint Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia
    Mark A Weiss
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Cornell University Medical College, New York, NY 10021, USA
    J Clin Oncol 21:1278-84. 2003
  9. pmc Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
    Jae H Park
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 118:1248-54. 2011
  10. ncbi request reprint Radioimmunotherapy of leukemia
    John M Burke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NewYork 10021, USA
    Adv Pharmacol 51:185-208. 2004

Detail Information

Publications21

  1. doi request reprint Radioimmunotherapy for hematopoietic cell transplantation
    Joseph G Jurcic
    Columbia University Medical Center, 177 Fort Washington Avenue, 6 435, New York, NY 10032, USA
    Immunotherapy 5:383-94. 2013
    ..While RIT has demonstrated significant antitumor activity, ultimately, randomized studies will be required to determine if conditioning regimens that include this therapeutic modality can improve patient outcomes after HCT...
  2. pmc Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    Todd L Rosenblat
    Department of Medicine and the Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5303-11. 2010
    ..This phase I/II trial was conducted to determine the maximum tolerated dose (MTD) and antileukemic effects of (213)Bi-lintuzumab, the first targeted α-emitter, after partially cytoreductive chemotherapy...
  3. pmc Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses
    Nicole Lamanna
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:491-7. 2009
    ..In that study, cyclophosphamide consolidation improved the frequency of complete response (CR) four-fold. Subsequently, rituximab was added to this regimen (F-->C-->R)...
  4. doi request reprint Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
    Azra Raza
    St Vincent s Comprehensive Cancer Center, New York, NY, USA
    Leuk Lymphoma 50:1336-44. 2009
    ..In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity...
  5. ncbi request reprint Immunotherapy for acute myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 458, New York, NY 10021, USA
    Curr Oncol Rep 7:339-46. 2005
    ..T-cell recognition of peptide antigens presented on the cell surface in combination with major histocompatibility complex antigen provides another potentially promising approach for the treatment of AML...
  6. ncbi request reprint The promise of targeted {alpha}-particle therapy
    Deborah A Mulford
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:199S-204S. 2005
    ..Treatment of patients with less-advanced disease and, ultimately, randomized trials comparing targeted alpha-particle therapy with standard approaches will be required to determine the clinical utility of this approach...
  7. ncbi request reprint Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Nicole Lamanna
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:1575-81. 2006
    ..We previously reported that pentostatin and cyclophosphamide (PC) is active and well-tolerated in patients with relapsed or refractory CLL. Subsequently, we added rituximab, and now report on this three-drug combination...
  8. ncbi request reprint Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia
    Mark A Weiss
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Cornell University Medical College, New York, NY 10021, USA
    J Clin Oncol 21:1278-84. 2003
    ..Of the purine analogs active in CLL, pentostatin may be least myelosuppressive. We hypothesized that combining pentostatin with cyclophosphamide would have less myelotoxicity than combinations using other purine analogs...
  9. pmc Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
    Jae H Park
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 118:1248-54. 2011
    ..These data highlight a need to educate health care providers across a wide range of medical fields, who may be the first to evaluate patients with APL, to have a major effect on early death and the cure rate of APL...
  10. ncbi request reprint Radioimmunotherapy of leukemia
    John M Burke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NewYork 10021, USA
    Adv Pharmacol 51:185-208. 2004
  11. ncbi request reprint Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin
    Timothy B Aliff
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 97:1025-32. 2003
    ..The authors treated a group of patients with amphotericin-refractory IFIs with the combination of caspofungin and amphotericin (or liposomal amphotericin)...
  12. doi request reprint Induction and postremission strategies in acute myeloid leukemia: state of the art and future directions
    Todd L Rosenblat
    Leukemia Service, Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Hematol Oncol Clin North Am 25:1189-213. 2011
    ..Until a greater proportion of individuals with AML attain long-term survival, patients should routinely be referred to cancer centers and enrolled in investigational studies...
  13. ncbi request reprint Antibody-based treatment of acute myeloid leukaemia
    Deborah A Mulford
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 458, New York, NY 10021, USA
    Expert Opin Biol Ther 4:95-105. 2004
    ....
  14. ncbi request reprint Antibody therapy in acute myeloid leukemia: current status and future directions
    John M Burke
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Lymphoma 2:S12-8. 2002
    ..Directed chemotherapy using the anti-CD33-calicheamicin conjugate gemtuzumab ozogamicin (Mylotarg) has produced remissions in patients with relapsed AML...
  15. doi request reprint What happened to anti-CD33 therapy for acute myeloid leukemia?
    Joseph G Jurcic
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Hematol Malig Rep 7:65-73. 2012
    ....
  16. ncbi request reprint Targeted alpha particle immunotherapy for myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 100:1233-9. 2002
    ..This study demonstrates the safety, feasibility, and antileukemic effects of (213)Bi-HuM195, and it is the first proof-of-concept for systemic targeted alpha particle immunotherapy in humans...
  17. pmc Emerging new approaches for the treatment of acute promyelocytic leukemia
    Jae Park
    Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
    Ther Adv Hematol 2:335-52. 2011
    ....
  18. ncbi request reprint Monitoring PML-RARalpha in acute promyelocytic leukemia
    Joseph G Jurcic
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 5:391-8. 2003
    ..APL provides a useful model in which therapy is targeted to an underlying genetic aberration and treatment is adapted based on monitoring of residual disease...
  19. ncbi request reprint A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia
    Mark A Weiss
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer 95:581-7. 2002
    ..The authors studied a regimen that contained high-dose cytarabine and a single high dose of idarubicin as salvage induction therapy for patients with recurrent or refractory lymphoblastic disease...
  20. ncbi request reprint Diagnosis and treatment of acute promyelocytic leukemia
    Joseph G Jurcic
    Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 9:337-44. 2007
    ..The lessons learned from APL have broad applications to other forms of leukemia and to cancer in general, whereby molecularly targeted therapy is directed to specifically defined subgroups...
  21. ncbi request reprint Radioimmunotherapy for acute leukemia
    John M Burke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Control 9:106-13. 2002
    ..In this article, we summarize the role of radioimmunotherapy in the treatment of leukemia...